natgillin/translations-raw huggingface dataset:
The Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that all marketing authorisations for the medicine be suspended throughout the European Union (EU) and that Octagam currently on the market be recalled. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri Agenciji je priporočil začasni umik dovoljenj za promet z zdravilom in odpoklic zdravila Octagam s tržišč po vsej Evropski uniji (EU).
The CHMP therefore recommended that, because of the safety concerns with Octagam, the marketing authorisations for the medicine be suspended in the EU. 
CHMP je zato priporočil, da je treba zaradi varnostnih zadržkov v povezavi z zdravilom Octagam dovoljenja za promet z zdravilom v EU začasno umakniti.
While the marketing authorisations are suspended, Octagam will not be available. 
Med začasnim umikom dovoljenj za promet z zdravilom zdravilo Octagam ne bo na voljo.
Its effect may improve further for up to six months. 
Njegov učinek se lahko dodatno povečuje še do šest mesecev.
It is available as tablets (10, 15 and 20 mg). 
Na voljo je v obliki tablet (10, 15 in 20 mg).
The medicine usually starts to have an effect after four to six weeks. 
Zdravilo navadno začne učinkovati po štirih do šestih tednih.
The full EPAR for Leflunomide medac can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Leflunomide medac je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The European Commission granted a marketing authorisation valid throughout the European Union for Leflunomide medac on 27 July 2010. 
Evropska komisija je dovoljenje za promet z zdravilom Leflunomide medac, veljavno po vsej Evropski uniji, izdala 27. julija 2010.
The recommended maintenance dose is 10 to 20 mg once a day in patients with rheumatoid arthritis, and 20 mg once a day in patients with psoriatic arthritis. 
Priporočeni vzdrževalni odmerek je od 10 do 20 mg enkrat na dan za bolnike z revmatoidnim artritisom in 20 mg enkrat na dan za bolnike s psoriatičnim artritisom.
This document is a summary of the European public assessment report (EPAR) for Leflunomide medac. 
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Leflunomide medac.
Leflunomide medac treatment usually starts with a ‘loading dose' of 100 mg once a day for three days, followed by a maintenance dose. 
Zdravljenje z zdravilom Leflunomide medac se običajno začne z „udarnim odmerkom“ v višini 100 mg enkrat na dan tri dni zapored, čemur sledi vzdrževalni odmerek.
What measures are being taken to ensure the safe and effective use of Leflunomide medac ? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Leflunomide medac?
Leflunomide medac is used to treat adults with active rheumatoid arthritis (an immune system disease causing inflammation of the joints) or active psoriatic arthritis (a disease causing red, scaly patches on the skin and inflammation of the joints). 
Zdravilo Leflunomide medac se uporablja za zdravljenje odraslih z aktivnim revmatoidnim artritisom (boleznijo imunskega sistema, ki povzroča vnetje sklepov) ali aktivnim psoriatičnim artritisom (boleznijo, ki povzroča rdeče, luskaste površine na koži in vnetje sklepov).
For more information about treatment with Leflunomide medac, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Leflunomide medac preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
This means that Leflunomide medac is similar to a ‘reference medicine' already authorised in the European Union (EU) called Arava. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Arava.
With fewer lymphocytes, there is less inflammation, helping to control the symptoms of arthritis. 
Zaradi manjšega števila limfocitov je vnetje manjše, kar pripomore k nadziranju simptomov artritisa.
The doctor should carry out blood tests to check the patient's liver, white blood cell counts and platelet counts before prescribing Leflunomide medac, and regularly during treatment. 
Zdravnik mora pri bolniku opraviti krvne preiskave za pregled delovanja jeter, števila belih krvničk in krvnih ploščic, preden predpiše zdravilo Leflunomide medac in nato v rednih presledkih med zdravljenjem.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Leflunomide medac. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Other information about Leflunomide medac: 
Druge informacije o zdravilu Leflunomide medac:
Because Leflunomide medac is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine's. 
Ker je zdravilo Leflunomide medac generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
Leflunomide medac treatment should be started and supervised by a specialist who has experience in the treatment of rheumatoid arthritis and psoriatic arthritis. 
Zdravljenje z zdravilom Leflunomide medac mora uvesti in nadzorovati zdravnik specialist, ki ima izkušnje z zdravljenjem revmatoidnega artritisa in psoriatičnega artritisa.
The CHMP concluded that, in accordance with EU requirements, Leflunomide medac has been shown to have comparable quality and to be bioequivalent to Arava. 
CHMP je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Leflunomide medac primerljivo raven kakovosti kot zdravilo Arava ter da mu je biološko enakovredno.
A risk management plan has been developed to ensure that Leflunomide medac is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Leflunomide medac je bil pripravljen načrt obvladovanja tveganj.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Leflunomide medac, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Leflunomide medac in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Leflunomide does this by blocking an enzyme called ‘dihydroorotate dehydrogenase', which is necessary for the lymphocytes to multiply. 
Leflunomid deluje tako, da zavira encim, imenovan „dihidroorotat dehidrogenaza“, ki je potreben za delitev limfocitov.
It reduces inflammation by reducing the production of immune cells called ‘lymphocytes', which are responsible for inflammation. 
Zdravilo ublaži vnetje z zmanjšanjem tvorjenja imunskih celic, imenovanih „limfociti“, ki povzročajo vnetje.
Leflunomide medac is a ‘generic medicine'. 
Leflunomide medac je „generično zdravilo“.
What are the benefit and risk of Leflunomide medac? 
Kakšne so koristi in tveganja, povezani z zdravilom Leflunomide medac?
Therefore, the CHMP's view was that, as for Arava, the benefit outweighs the identified risk. 
Zato je menil, da njegove koristi tako kot pri zdravilu Arava odtehtajo znana tveganja.
Because Leflunomide medac is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Arava. 
Ker je zdravilo Leflunomide medac generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Arava.
The Committee recommended that Leflunomide medac be given marketing authorisation. 
Priporočil je, da se za zdravilo Leflunomide medac izda dovoljenje za promet.
Leflunomide medac is a medicine that contains the active substance leflunomide. 
Leflunomide medac je zdravilo, ki vsebuje zdravilno učinkovino leflunomid.
Why has Leflunomide medac been approved? 
Zakaj je bilo zdravilo Leflunomide medac odobreno?
The active substance in Leflunomide medac, leflunomide, is an immunosuppressant. 
Zdravilna učinkovina zdravila Leflunomide medac, leflunomid, je zdravilo za zaviranje imunskega odziva.
How has Leflunomide medac been studied? 
Kako je bilo zdravilo Leflunomide medac raziskano?
What is Leflunomide medac? 
Kaj je zdravilo Leflunomide medac?
What is Leflunomide medac used for? 
Za kaj se zdravilo Leflunomide medac uporablja?
How does Leflunomide medac work? 
Kako zdravilo Leflunomide medac deluje?
How is Leflunomide medac used? 
Kako se zdravilo Leflunomide medac uporablja?
3 x 28 tablets 
3 x 28 tablet
From a microbiological point of view, the product should be used immediately. 
Z mikrobiološkega vidika je treba izdelek uporabiti nemudoma.
It is available in packs of: 
Na voljo v pakiranjih:
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 14 September 2015 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 14. september 2015
* Definition of frequency terms: Very common - ≥ 10 %; Common - > 5 % and < 10 %. 
* Definicija pogostnosti: Zelo pogosto - > 10 %; Pogosto - > 5 % in < 10 %.
If you are pregnant, think you may be pregnant or are planning to have a baby, tell your doctor. 
Če ste noseči, mislite, da bi lahko bili noseči, ali načrtujete nosečnost, to povejte zdravniku.
If you are unsure, ask your doctor or pharmacist if any of your medicines are NSAIDs. 
Če niste prepričani, vprašajte zdravnika ali farmacevta, ali so katera od vaših zdravil NSAIDi.
Frequency estimate: Very common (≥ 1/10), Common (≥ 1/100 to < 1/10), Uncommon (≥ 1/1,000 to < 1/100), Rare (≥ 1/10,000 to < 1/1,000), Very rare (< 1/10,000) and not known (cannot be estimated from available data). 
Pogostnosti so določene kot: zelo pogosto (≥ 1/10), pogosto ( 1/100 do < 1/10), občasno (≥ 1/1000 do < 1/100), redko (≥ 1/10.000 do < 1/1000), zelo redko (<1/10.000) in ni znano (ni mogoče oceniti iz razpoložljivih podatkov).
Based on the planned date of your infusion of Pemetrexed Lilly and/or on the status of your kidney function, your doctor needs to advise you on which medicines you can take and when you can take them. 
Na podlagi načrtovanega datuma vaše infuzije zdravila Pemetreksed Lilly in/ali glede na delovanje vaših ledvic vam mora zdravnik svetovati, katera zdravila lahko jemljete in kdaj jih lahko jemljete.
It is unknown whether pemetrexed is excreted in human milk and adverse reactions on the suckling child cannot be excluded. 
Ni znano, ali se pemetreksed izloča v materino mleko, in neželenih reakcij za dojenčka ne moremo izključiti.
Not known: frequency cannot be estimated from the available data Lower limb swelling with pain and redness Increased urine output 
Ni znano: pogostnosti ni mogoče oceniti na podlagi razpoložljivih podatkov Otekanje spodnjih okončin z bolečino in rdečino Povečano izločanje urina
Driving and using machines Pemetrexed Lilly may make you feel tired. 
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo Pemetreksed Lilly lahko povzroči, da se boste počutili utrujene.
Very common (may affect more than 1 in 10 people) Low white blood cells 
Zelo pogosti neželeni učinki (pojavijo se lahko pri več kot 1 od 10 bolnikov) Nizko število belih krvnih celic
Creatinine clearance decreased** 
Povišan kreatinin Znižan očistek kreatinina**
Please tell your doctor if you are taking any medicine for pain or inflammation (swelling), such as medicines called “nonsteroidal anti-inflammatory drugs” (NSAIDs), including medicines purchased without a doctor's prescription (such as ibuprofen). 
Prosimo, povejte zdravniku, če jemljete kaka zdravila proti bolečinam ali vnetju (oteklinam), denimo zdravila, imenovana “nesteroidna protivnetna zdravila” (NSAID-i), vključno z zdravili, ki ste jih dobili brez recepta (kot denimo, ibuprofen).
The European Medicines Agency has waived the obligation to submit the results of studies with the reference medicinal product containing pemetrexed in all subsets of the paediatric population in the granted indications (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z referenčnim zdravilom, ki vsebuje pemetreksed, za vse podskupine pediatrične populacije za odobrene indikacije zdravila (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not be longer than 24 hours at 2 °C to 8 °C. 
Če zdravila, pripravljenega za uporabo, ne uporabimo takoj, je za čase shranjevanja in pogoje pred uporabo odgovoren uporabnik, in naj bi ne presegali 24 ur pri 2 do 8 C.
In vitro studies indicate that pemetrexed is actively secreted by OAT3 (organic anion transporter. 
In vitro študije so pokazale, da se pemetreksed aktivno izloča z OAT3 (prenašalcem organskih anionov).
Calculate the dose and the number of Pemetrexed Lilly vials needed. 
Izračunajte odmerek in število potrebnih vial zdravila Pemetreksed Lilly.
Lilly France Zone Industrielle 2 Rue du Colonel Lilly 67640 Fegersheim France 
Lilly France Zone Industrielle 2 Rue du Colonel Lilly 67640 Fegersheim Francija
Safety was assessed for patients who were randomised to receive pemetrexed (N = 800). 
Varnost je bila ocenjena pri bolnikih, ki so bili naključno izbrani za prejemanje pemetrekseda (N = 800).
** In the pemetrexed/cisplatin arm, randomized and treated (N = 225) and fully supplemented (N = 167) 
**V veji zdravljenja s pemetreksedom/cisplatinom, randomizirani in zdravljeni (N = 225) ter s popolnim dopolnjevanjem (N = 167).
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu. 
Podrobne informacije o tem zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu.
Before each infusion you will have samples of your blood taken to evaluate if you have sufficient kidney and liver function and to check that you have enough blood cells to receive Pemetrexed Lilly. 
Pred vsako infuzijo vam bomo odvzeli vzorce krvi za vrednotenje delovanja vaših ledvic in jeter ter oceno, ali imate dovolj krvnih celic za prejemanje zdravila Pemetreksed Lilly.
Alkaline phosphatase (AP), aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) should be ≤ 3 times upper limit of normal. 
Alkalna fosfataza (AF), aspartatna aminotransferaza (AST ali SGOT) in alaninska aminotransferaza (ALT ali SGPT) morajo biti  3-kratnik zgornje meje normalnih vrednosti.
Creatinine clearance should be ≥ 45 mL/min. 
Očistek kreatinina mora biti  45 ml/min.
Annex IV Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s) 
Priloga IV Znanstveni zaključki in podlaga za spremembo pogojev dovoljenj(a) za promet z zdravilom
Reconstituted and infusion solution: The product should be used immediately. 
Rekonstituirane raztopine in raztopine za infundiranje: zdravilo moramo uporabiti nemudoma.
What Pemetrexed Lilly is and what it is used for 
Kaj je zdravilo Pemetreksed Lilly in za kaj ga uporabljamo
Your doctor will discuss with you the potential risk of taking Pemetrexed Lilly during pregnancy. 
Z zdravnikom se pogovorite o možnem tveganju pri prejemanju zdravila Pemetreksed Lilly v času nosečnosti.
A total of 169 patients (47.1 %) completed ≥ 6 cycles maintenance treatment with pemetrexed, representing at least 10 total cycles of pemetrexed. 
Skupno je 169 bolnikov (47,1 %) zaključilo ≥ 6 ciklov vzdrževalnega zdravljenja s pemetreksedom, kar predstavlja vsaj 10 polnih ciklov pemetrekseda.
At the time of this final survival analysis, 28.7 % of patients were alive or lost to follow up on the pemetrexed arm versus 21.7 % on the placebo arm. 
V času te končne analize preživetja je bilo živih ali ni bilo na voljo za nadaljnje spremljanje 28,7 % bolnikov v kraku s pemetreksedom, v primerjavi z 21,7 % v kraku s placebom.
Side effects with Pemetrexed Lilly may include: 
Neželeni učinki z zdravilom Pemetreksed Lilly lahko vključujejo:
Upon recovery patients should be retreated using the guidelines in Tables 1, 2 and 3, which are applicable for Pemetrexed Lilly used as a single agent or in combination with cisplatin. 
Po okrevanju bolnike ponovno zdravimo z uporabo smernic v Preglednicah 1, 2 in 3, ki veljajo za zdravilo Pemetreksed Lilly, če ga uporabljamo kot edino učinkovino ali v kombinaciji s cisplatinom.
Men are advised not to father a child during and up to 6 months following treatment with Pemetrexed Lilly and should therefore use effective contraception during treatment with Pemetrexed Lilly and for up to 6 months afterwards. 
Moškim odsvetujemo, da bi v času zdravljenja z zdravilom Pemetreksed Lilly ter do 6 mesecev po zdravljenju s tem zdravilom spočeli otroka, zato naj v času zdravljenja z zdravilom Pemetreksed Lilly ter do 6 mesecev po zdravljenju s tem zdravilom uporabljajo učinkovito kontracepcijo.
What Pemetrexed Lilly is and what it is used for What you need to know before you use Pemetrexed Lilly How to use Pemetrexed Lilly Possible side effects 
Kaj je zdravilo Pemetreksed Lilly in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Pemetreksed Lilly Kako uporabljati zdravilo Pemetreksed Lilly Možni neželeni učinki
The dose of Pemetrexed Lilly is 500 milligrams for every square metre of your body's surface area. 
Odmerek zdravila Pemetreksed Lilly je 500 miligramov za vsak kvadratni meter površine vašega telesa.
Pemetrexed total systemic clearance is 91.8 mL/min and the elimination half-life from plasma is 3.5 hours in patients with normal renal function (creatinine clearance of 90 mL/min). 
Celotni sistemski očistek pemetrekseda je 91,8 ml/min, razpolovni čas izločanja iz plazme je 3,5 ur pri bolnikih z normalnim ledvičnim delovanjem (očistek kreatinina 90 ml/min).
Pancytopenia- combined low counts of white cells, red cells and platelets Radiation pneumonitis (scarring of the air sacs of the lung associated with radiation therapy) may occur in patients who are also treated with radiation either before, during or after their Pemetrexed Lilly therapy. 
Pancitopenija - skupno nizko število belih krvnih celic, rdečih krvnih celic in trombocitov Radiacijska pljučnica (brazgotinjenje pljučnih mešičkov, povezano z obsevanjem) se lahko pojavi pri bolnikih, ki so zdravljeni tudi z obsevanjem pred, med ali po zdravljenju z zdravilom Pemetreksed Lilly.
Pharmacotherapeutic group: Antineoplastic agents, antimetabolites, folic acid analogues, ATC code: L01BA04 
Farmakoterapevtska skupina: zdravila z delovanjem na novotvorbe, zaviralci celične presnove (antimetaboliti), analogi folne kisline, oznaka ATC: L01BA04
In clinical studies, patients with creatinine clearance of ≥ 45 mL/min required no dose adjustments other than those recommended for all patients. 
V kliničnih študijah bolniki z očistkom kreatinina  45 ml/min niso potrebovali prilagajanja odmerkov, razen tistih prilagoditev, ki jih priporočamo za vse bolnike.
If you have an accumulation of fluid around your lungs, your doctor may decide to remove the fluid before giving you Pemetrexed Lilly. 
Če se vam okrog pljuč nabira tekočina, se bo zdravnik morda odločil tekočino pred dajanjem zdravila Pemetreksed Lilly odstraniti.
A significant increase in the incidence of possibly study-drug-related Grade 3/4 neutropenia was observed with longer exposure to pemetrexed (≤ 6 cycles: 3.3 %, > 6cycles: 6.4 %: p = 0.046). 
Znatno povečanje pojavnosti nevtropenije stopnje 3/4, ki je lahko povezano s preučevanim zdravilom, so opazili pri dolgotrajnejši izpostavljenosti pemetreksedu (≤ 6 ciklov: 3,3 %, > 6 ciklov: 6,4 %: p = 0,046).
Treatment with Pemetrexed Lilly should be discontinued if a patient experiences any haematologic or non-haematologic Grade 3 or 4 toxicity after 2 dose reductions or immediately if Grade 3 or 4 neurotoxicity is observed. 
Zdravljenje z zdravilom Pemetreksed Lilly moramo prekiniti, če bolnik izkusi kakršnokoli hematološko ali nehematološko toksičnost stopnje 3 ali 4 po 2 znižanjih odmerka ali nemudoma, če opazimo nevrološko toksičnost stopnje 3 ali 4.
When using Pemetrexed Lilly in combination with cisplatin: 
Kadar uporabljamo zdravilo Pemetreksed Lilly v kombinaciji s cisplatinom:
The other ingredients are mannitol (E421), hydrochloric acid and sodium hydroxide (see section 2 “Pemetrexed Lilly contains sodium”) 
Pomožne snovi so manitol (E421), klorovodikova kislina in natrijev hidroksid (glejte poglavje 2 »Zdravilo Pemetreksed Lilly vsebuje natrij«).
An insufficient number of patients has been studied with creatinine clearance of below 45 mL/min. 
Zadostnega števila bolnikov z očistkom kreatinina pod 45 ml/min niso preučili.
How to store Pemetrexed Lilly Contents of the pack and other information 
Shranjevanje zdravila Pemetreksed Lilly Vsebina pakiranja in dodatne informacije
What you need to know before you use Pemetrexed Lilly 
Kaj morate vedeti, preden boste uporabili zdravilo Pemetreksed Lilly
Do not use Pemetrexed Lilly - if you are allergic (hypersensitive) to pemetrexed or any of the other ingredients of this medicine (listed in section 6). 
Ne uporabljajte zdravila Pemetreksed Lilly: - če ste alergični na (preobčutljivi za) pemetreksed ali na katerokoli sestavino tega zdravila
Immune-mediated haemolytic anaemia (antibody-mediated destruction of red blood cells) Hepatitis (inflammation of the liver) 
Imunsko pogojena hemolitična anemija (propad rdečih krvnih celic, ki ga povzročijo protitelesa) Hepatitis (vnetje jeter)
If you currently have or have previously had problems with your kidneys, talk to your doctor or hospital pharmacist as you may not be able to receive Pemetrexed Lilly. 
Če imate ali ste imeli težave z ledvicami, se pogovorite z zdravnikom ali bolnišničnim farmacevtom, ker morda ne boste mogli prejeti zdravila Pemetreksed Lilly.
Children and adolescents There is no relevant use of Pemetrexed Lilly in the paediatric population 
Otroci in mladostniki Zdravilo Pemetreksed Lilly ni primerno za uporabo pri pediatrični populaciji.
The incidence of adverse reactions was evaluated for patients who received ≤ 6 cycles of pemetrexed maintenance (N = 519), and compared to patients who received > 6 cycles of pemetrexed (N = 281). 
Pojavnost neželenih učinkov so ocenili za bolnike, ki so prejeli ≤ 6 ciklov vzdrževalnega zdravljenja s pemetreksedom (N = 519) in jo primerjali z bolniki, ki so prejeli > 6 ciklov pemetrekseda (N = 281).
You will always receive Pemetrexed Lilly by infusion into one of your veins. 
Zdravilo Pemetreksed Lilly boste vedno prejeli v obliki infuzije v veno.
Overall response rate** (95 % CI) 
Skupna stopnja odziva** (95 % IZ)
Cisplatin is also given by infusion into one of your veins, and is given approximately 30 minutes after the infusion of Pemetrexed Lilly has finished. 
Cisplatin tudi dajemo v obliki infuzije v veno, približno 30 minut po zaključku infuzije zdravila Pemetreksed Lilly.
The use of Pemetrexed Lilly should be avoided during pregnancy. 
Uporabi zdravila Pemetreksed Lilly med nosečnostjo se izogibamo.
Therefore, the use of pemetrexed in patients with creatinine clearance of < 45 mL/min is not recommended (see section 4.2). 
Zato uporabe pemetrekseda pri bolnikih z očistkom kreatinina < 45 ml/min ne priporočamo (glejte poglavje 4.2).
75 % of previous dose (both Pemetrexed Lilly and cisplatin) 
75 % predhodnega odmerka (zdravila Pemetreksed Lilly in cisplatina)
*** Integrated adverse reactions table combines the results of the JMEN pemetrexed maintenance (N = 663) and PARAMOUNT continuation pemetrexed maintenance (N = 539) studies. 
*** Skupna preglednica neželenih učinkov združuje rezultate študij vzdrževalnega zdravljenja samo s pemetreksedom JMEN (N = 663) in nadaljevalnega zdravljenja s pemetreksedom (PARAMOUNT: N = 539).